 preoper chemotherapi cisplatin fluorouracil radiat therapi stage iii non-small-cel lung cancer phase II studi lung cancer studi group lung cancer studi group phase II pilot studi concurr chemotherapi radiat therapi chemoradiotherapi surgeri elig patient non-small-cel cancer chest attempt resect residu diseas advanc stage iiia minim stage iiib diseas cisplatin day fluorouracil hour continu infus day day radiat Gy fraction day patient complet respons patient partial respons overal respons rate toxic chemoradiotherapi moder accept eight week therapi patient underw thoracotomi tumor resect complet resect incomplet resect surgic dissect difficult patient chemoradiotherapi appar increas postop complic patient viabl tumor resect specimen patient tumor diseas recurr none recurr chest recurr distant site develop second primari tumor median surviv patient month overal result major benefit preoper chemoradiotherapi regimen patient advanc resect non-small-cel lung cancer result need rel role preoper radiotherapi chemotherapi